Zanzalintinib not checked

Exelixis · XL092

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
16 active
17 in total · 9 in the EU
Targets
MET · VEGFR2 · AXL · Mer
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
Tested for
Colorectal Cancer (4 trials), Renal Cell Carcinoma (3 trials), Cancer (2 trials), Renal Cell Carcinoma (RCC) (2 trials), Hepatocellular Carcinoma (HCC) (2 trials), Non-Clear Cell Renal Cell Carcinoma (nccRCC) (2 trials), Solid Tumor (2 trials), Non-Clear Cell Renal Cell Carcinoma and 26 more
Main trialPhase 3
“The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.”In the company’s words, NCT05425940 on ClinicalTrials.gov
Other names
XL092

Other drugs for Colorectal Cancer

All 392 drugs for Colorectal Cancer

Coming up12

Changes1

Last 90 days

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 16 Jun 2026 Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Phase 3Active, not recruiting 15 Dec 2026 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
Phase 3Recruiting 5 Apr 2030 Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Phase 3Enrolling by invitation 31 May 2030 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Phase 3Recruiting 27 Nov 2030 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Phase 3Recruiting 27 Feb 2032 A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Phase 2/3Active, not recruiting Aug 2028 Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2/3Recruiting 30 Jun 2029 Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase 2Recruiting 29 Feb 2028 A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Phase 2Recruiting 15 Jun 2028 Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2Recruiting 26 Oct 2031 Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Phase 1Recruiting Dec 2025 Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Phase 1Active, not recruiting 31 Aug 2026 A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Phase 1Recruiting 31 Jan 2027 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Phase 1Recruiting 31 May 2027 A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
Phase 1Not yet recruiting 31 Jul 2028 Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase 1Terminated 12 May 2025 Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Zanzalintinib

Following is part of Solo: you see every change to Zanzalintinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in